Chemeq silent on ASIC query
09 September, 2004 by Graeme O'NeillPerth veterinary drug developer Chemeq Limited (ASX:CMQ) has announced it will issue a replacement prospectus after the Australian Securities and Investments Commission placed an interim stop order on the prospectus it issued late last month for a rights issue to raise $9.94 million.
Avexa ready for market, says Amrad
08 September, 2004 by Melissa TrudingerAmrad (ASX:AML) spin-out Avexa is ready to list following shareholder approval of the demerger and the granting of Federal Court approval of the scheme of arrangement.
Cryptopharma nets $1.5m Start grant
07 September, 2004 by Melissa TrudingerUniversity of Melbourne spin-off Cryptopharma has been awarded a AUD$1.5 million R&D Start grant to support its respiratory therapeutics program.
Japanese patent win boosts Optiscan
03 September, 2004 by Renate KrelleA patent win for confocal-miscroscope company Optiscan (ASX:OIL) in Japan will increase the company’s licensing revenues for the benchtop applications of its technology in Japan by up to AUD$400,000, according to Optiscan.
Warm welcome for Bone Medical on ASX
03 September, 2004 by Melissa TrudingerBone Medical (ASX: BNE) today became the latest in a steady trickle of biotech companies to list on the ASX, making its debut at AUD$0.80, a substantial gain on its placement price of $0.60.
Australia's TGA to merge with NZ's Medsafe
01 September, 2004 by Renate KrelleIt’s a fair bet that the Therapeutic Goods Administration is currently making like a duck. Although the regulator may present a calm front to the world, below the surface it is paddling like mad, preparing for a huge shift from life as a local regulator to that of a new trans-Tasman joint agency.
Scigen to raise up to $16m, Russia's Shreya to take stake
01 September, 2004 by Renate KrelleHaving announced a revenue increase of 79 per cent to S$6.5 million and a loss of S$4.31 million for the year ended June 30, Singapore-based generics company Scigen (ASX:SIE) will be topping up its coffers with a private placement to Indian-Russian marketing partner Shreya, and a rights issue to existing shareholders.
Eqitx appoints chief executive officer
01 September, 2004 by Renate KrelleMelbourne-based Equitx (ASX:EQX) has appointed former Agenix vice president Sue Parry-Jones as chief executive officer.
CCC to move to Cambridge
31 August, 2004 by Graeme O'NeillPerth tissue-engineering biomedical company Clinical Cell Culture(ASX:CCE) will transplant most of its corporate activities from Perth to Cambridge after gaining approval from the British Medicines and Healthcare Products Regulatory Agency to market its Cellspray and Cellspray XP products in the UK.
PlasVacc to raise $5m for US purchase
25 August, 2004 by Melissa TrudingerPublic unlisted animal plasma company PlasVacc has filed a prospectus with Asic to raise AUD$4.75 million to fund its planned acquisition of Californian equine plasma company Veterinary Dynamics (VDI).
Circadian returns capital to investors
25 August, 2004 by Melissa TrudingerLong-time biotech investment group Circadian (ASX: CIR) is planning to return AUD$0.50 cents per share to investors after posting a $5.8 million profit for the 2003-2004 financial year with an even better profit forecast for next year.
ARC research networks up and running
25 August, 2004 by Susan WilliamsonThe Australian Research Council’s Research Network Program is out of the starting gates. It was announced today that 24 new research networks will be established across Australia with $42 million in funding from the federal government.
P3 round two funding up for grabs
25 August, 2004 by Renate KrelleResearch and development funding is up for grabs once more under round two of the federal government’s $150 million Pharmaceuticals Partnerships Program – known as P3 – which opened for applications today.
Amrad on track, with global ambitions
23 August, 2004 by Melissa TrudingerAmrad's (ASX: AML) annual results were in line with company expectations for the financial year and were an indication of the progress made in building and restructuring the management team for future growth, chairman Bob Moses said today.
Chemeq CEO to step down
23 August, 2004 by Melissa TrudingerAs Chemeq (ASX: CMQ) continues its efforts to raise capital through a placement to institutional and sophisticated investors, CEO and chairman Graham Melrose has announced plans to step down from the CEO role, remaining non-executive chairman.
